Advertisement
Advertisement
Business /

Investor Relations

METiS TechBio debuts on Hong Kong stock market and raises HK$2.11 billion (US$269.5 million) from the sale of 201.23 million shares at HK$10.50 each. Photo: Jelly Tse
Banking & finance

Hong Kong-listed firm uses AI to make nano-rockets to deliver life-saving drugs

METiS TechBio debuts on Hong Kong stock market as its CEO compares the drug design start-up to SpaceX for the pharmaceutical industry.

videocam
IPO

Chinese industrial robot maker Inovance joins Hong Kong IPO queue

IPO

China’s solar giant Sungrow revives Hong Kong IPO plan amid clean energy boom

Banking & finance

Biotech-led boom as 8 China firms flock to Hong Kong’s thriving stock market

AI-powered drug developer Metis TechBio leads group that includes developers of autonomous driving technology and industrial robots.

Healthcare led liquidity growth on the Hong Kong stock market over the past decade, with trading turnover for the sector surging more than 11-fold between 2015 and 2025. Photo: Shutterstock
Healthcare led liquidity growth on the Hong Kong stock market over the past decade, with trading turnover for the sector surging more than 11-fold between 2015 and 2025. Photo: Shutterstock
Banking & finance

HKEX proposes halving settlement cycle to boost Hong Kong’s financial profile

Bourse operator launches a consultation on shortening the share settlement cycle to one day, aiming to implement the reform in late 2027.

IPO

Sigenergy jumps 103% in Hong Kong debut on rising energy storage demand

The Shanghai-based firm’s shares closed at HK$659.50, versus its offer price of HK$324.20 after it raised US$560 million from its IPO.

Advertisement
Advertisement
Advertisement
Banking & finance

Global funds fuel Hong Kong IPO rebound as investors rebalance China portfolios

AI, robotics and energy storage firms make up most of the record-high IPO pipeline in Hong Kong, says Chan.

HKEX CEO Bonnie Chan Yiting speaks at the Chinese New Year Market Open Celebration at HKEX in Central, on February 20. Photo: Karma Lo
HKEX CEO Bonnie Chan Yiting speaks at the Chinese New Year Market Open Celebration at HKEX in Central, on February 20. Photo: Karma Lo
IPO

Huaqin’s US$580 million Hong Kong share sale attracts JPMorgan and UBS

The Shanghai-listed firm is selling 58.55 million shares, pricing them at a 31.2 per cent discount to their last-traded mainland stock price.

Banking & finance

Stricter Chinese scrutiny of offshore vehicles a blow for tech IPO candidates

Mainland’s stock market watchdog is discouraging establishment of ‘red-chip-structured’ companies in sensitive industries.

IPO

Hong Kong retains IPO crown but may lose to US mega listings over full year

Second place for IPO funds raised is Nasdaq, with US$5.65 billion from 18 listings, while the New York Stock Exchange ranks third.

An exterior view of the Hong Kong stock exchange in Central, February 6, 2026. Photo: Jonathan Wong
Banking & finance

Chinese company to use AI-powered testing to boost profits and fast-track IVF

China’s falling fertility rate sees spike in demand for assisted reproduction as biotech firm raises US$101 million from Hong Kong listing.

videocam
A Chinese biotech company is hoping AI technology will help to boost profits and speed up chromosome testing which is a vital part of In vitro fertilisation. Photo: Dreamstime/TNS
A Chinese biotech company is hoping AI technology will help to boost profits and speed up chromosome testing which is a vital part of In vitro fertilisation. Photo: Dreamstime/TNS
Banking & finance

Insilico Medicine signs AI drug development deal with Eli Lilly

Reaching development, regulatory and commercial milestones could see value of deal hit around US$2.75 billion.

Banking & finance

Tong Ren Tang unit pulls Hong Kong IPO in first postponement this year

Hospital-network operator delays plan to raise up to US$115 million amid tepid demand.

videocam
Banking & finance

HKIC, Gobi Partners and HKU launch fund to back university research start-ups

Gobi-HKU Fund I makes first bets at launch, investing in robotics and AI drug design spin-offs born from university research breakthroughs.

The partnership with HKU will help bridge the gap between research and commercialisation, according to Gobi Partners. Photo: Dickson Lee
Hong Kong stock market

SFC prepares to inspect Hong Kong IPO listing sponsors amid quality concerns

Market regulator will soon begin inspection of investment banks amid concerns about deficiencies in listing documents and misconduct.

The inspection will focus on whether banks have complied with a circular outlining expectations on staffing and quality controls when handling IPOs, according to the SFC. Photo: Yik Yeung-man
The inspection will focus on whether banks have complied with a circular outlining expectations on staffing and quality controls when handling IPOs, according to the SFC. Photo: Yik Yeung-man
China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.

Hong Kong stock market

Hong Kong stocks edge higher as oil steadies, tracking Wall Street gains

Hang Seng Index advances for a second day amid easing concerns over inflation and geopolitical risks.

Advertisement
Advertisement
Advertisement
Banking & finance

Hong Kong attracts wave of biotech IPO filings amid AI drug research boom

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest.

The latest applications come as healthcare and biotechnology equity capital market activity in Hong Kong reached US$15.6 billion last year. Illustration: Shutterstock
The latest applications come as healthcare and biotechnology equity capital market activity in Hong Kong reached US$15.6 billion last year. Illustration: Shutterstock
Banking & finance

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.

IPO

Hong Kong’s IPO pace picks up as 2 mainland Chinese firms get listing approval

Everdisplay Optronics and Galaxis Technology publish post-hearing information packs on the Hong Kong stock exchange.

Insilico

Insilico Medicine advances Middle East push with UAE AI drug discovery deal

Hong Kong-listed biotech firm’s shares jump after announcing partnership to use AI tools in drug discovery in the United Arab Emirates.

The agreement was reached during the World Health Expo in Dubai between February 9 and 12, about two weeks before the United States and Israel launched military strikes on Iran. Photo: Shutterstock
Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

The logo of Sino Biopharmaceutical is seen on a building in Beijing, April 22, 2021. Photo: VCG via Getty Images
The logo of Sino Biopharmaceutical is seen on a building in Beijing, April 22, 2021. Photo: VCG via Getty Images
IPO

HSBC chairman floats ‘IPO connect’ for Hong Kong, Shenzhen listings

Modelled on Stock Connect, the proposal would give investors in the Greater Bay Area cross-border access to new share listings.

Hong Kong stock market

The big cornerstone comeback: what’s driving investors back to Hong Kong IPOs?

After four subdued years, the cornerstone investors that anchor Hong Kong’s IPO market are returning in force, reshaping the deal landscape.

China stock market

US investors increase buying of Hong Kong, mainland Chinese stocks

American investors bought US$15 billion of Hong Kong and mainland stocks in 2025, as buying picked up steam through the year.

A man walks on illuminated stairs at M+ Museum in West Kowloon as Hong Kong’s skyline is seen in a reflection on May 28, 2025. Photo: Eugene Lee
Help preserve 120 years of quality journalism.
SUPPORT NOW